SANGAMO THERAPEUTICS, INC: ARMISTICE CAPITAL, LLC amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Armistice Capital, LLC amended its Schedule 13G stake filing for Sangamo Therapeutics, Inc., disclosing the change to the SEC under accession number 0001172661-26-005253. The filing updates the investment firm's previously reported beneficial ownership position in the gene-editing and genomic medicine company. Schedule 13G amendments are typically filed by investors with passive or qualified institutional holdings, and the revised figures signal a shift in Armistice's position size. The disclosure matters because large institutional holders can influence Sangamo's shareholder base and governance dynamics. Investors will watch for the specific ownership percentage and share count in the amended filing, along with any subsequent 13G or 13D updates that clarify Armistice's intent.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Armistice Capital, LLC, Sangamo Therapeutics, Inc.